Coronavirus: India will produce 100 million doses of Russian Sputnik V vaccine

A medic of the regional hospital receives Russia’s “Sputnik V” vaccine shot against the coronavirus disease in Tver, Russia. (Reuters)

Russia’s sovereign wealth fund and Indian pharmaceutical company Hetero have agreed to produce over 100 million doses per year in India of the Sputnik V vaccine against COVID-19, according to a statement on the Sputnik V Twitter account on Friday.

Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021, the statement said.

Phase II-III trials are ongoing in India, the statement said. Drugmaker Dr Reddy’s Laboratories Ltd has said it expects late-stage trials to be completed by as early as March 2021.

Read more:

Coronavirus: WHO sees progressive control of COVID-19 in 2021, cautions on Christmas

Coronavirus: Five COVID-19 patients killed in India hospital fire

Coronavirus: UAE officials expect vaccine to be available by end of 2020, early 2021

Last Update: Friday, 27 November 2020 KSA 10:09 - GMT 07:09